Notice of Meeting: Secretary's Advisory Committee on Genetics, Health, and Society, 9541-9542 [07-965]
Download as PDF
Federal Register / Vol. 72, No. 41 / Friday, March 2, 2007 / Notices
pwalker on PROD1PC71 with NOTICES
Biological Materials Availability:
Biological materials related to this
technology are not available at this time.
Licensing Availability: This
application is available for license on a
non-exclusive or exclusive basis.
Licensing Contact: Susan S. Rucker;
301/435–4478; e-mail:
ruckersu@mail.nih.gov.
Dated: February 22, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–3695 Filed 3–1–07; 8:45 am]
Genes Expressed in Prostate Cancer
and Methods of Use
Description of Technology: This
invention is a novel gene, called New
Gene Expressed in Prostate (NGEP).
This gene appears to be expressed only
in human prostate and prostate cancer.
This gene has two known splice variants
of significantly different size. The
shorter splice variant encodes a
cytoplasmic protein, while the longer
splice variant encodes a plasma
membrane protein, which has been
detected on the plasma membrane of
human cancer cells.
This patent application contains
claims to the polypeptide, NGEP,
nucleotides encoding NGEP, antibodies
that bind NGEP polypeptides, and
methods of using these polypeptides,
polynucleotides, and antibodies.
The presence of the protein on the
cell surface and the selective expression
in prostate and prostate cancer make
this a potential target for prostate cancer
diagnostics and therapeutics. Potential
therapeutics could be gene-based,
vaccines, antibodies, or
immunoconjugates.
Inventors: Ira Pastan, Tapan Bera, and
Byungkook Lee (NCI.)
Publications:
1. S Das et al. NGEP, a prostatespecific plasma membrane protein that
promotes the association of LNCaP cells.
Cancer Res. 2007 Feb 15; 67(4):1594–
1601.
2. TK Bera et al. NGEP, a gene
encoding a membrane protein detected
only in prostate cancer and normal
prostate. Proc Natl Acad Sci USA. 2004
Mar 2; 101(9):3050–3064.
Patent Status:
1. U.S. Provisional Application No.
60/461,399 filed 08 Apr 2003 (HHS
Reference No. E–148–2003/0–US–01).
2. PCT Application No. PCT/US04/
10588 filed 05 Apr 2004, which
published as WO 2004/092213 on 28
Oct 2004 (HHS Reference No. E–148–
2003/0–PCT–02).
3. U.S. Patent Application No. 10/
552,515 filed 06 Oct 2005 (HHS
Reference No. E–148–2003/0–US–03).
Licensing Status: Available for nonexclusive licensing.
Licensing Contact: Jesse S. Kindra,
J.D.; 301/435–5559;
kindraj@mail.nih.gov.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
VerDate Aug<31>2005
18:44 Mar 01, 2007
Jkt 211001
BILLING CODE 4140–01–P
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
Office of AIDS Research Advisory
Council.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: Office of AIDS
Research Advisory Council.
Date: April 19, 2007.
Time: 9 a.m. to 5 p.m.
Agenda: The meeting will focus on HIVrelated Complications including
Malignancies, Cardiovascular Disease, and
Metabolic Complications. An update will be
provided on the OARAC Working Groups for
Treatment and Prevention Guidelines.
Place: National Institutes of Health, 5635
Fishers Lane, Rockville, MD 20852.
Contact Person: Christina Brackna,
Coordinator, Program Planning and Analysis,
Office of Aids Research, Office of the
Director, NIH, 5635 Fishers Lane MSC 9310,
Suite 4000, Rockville, MD 20852, (301) 402–
8655, cm53v@nih.gov.
Any member of the public interested in
presenting oral comments to the committee
may notify the Contact Person listed on this
notice at least 10 days in advance of the
meeting. Interested individuals and
representatives of organizations may submit
a letter of intent, a brief description of the
organization represented, and a short
description of the oral presentation. Only one
representative of an organization may be
allowed to present oral comments and if
accepted by the committee, presentations
may be limited to five minutes. Both printed
and electronic copies are requested for the
record. In addition, any interested person
may file written comments with the
committee by forwarding their statement to
the Contact Person listed on this notice. The
statement should include the name, address,
telephone number and when applicable, the
business or professional affiliation of the
interested person.
Information is also available on the
Institute’s Center’s home page: https://
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
9541
www.ni.gov/od/oar/index.htm, where an
agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.14, Intramural Research
Training Award; 93.22, Clinical Research
Loan Repayment Program for Individuals
from Disadvantaged Backgrounds; 93.232,
Loan Repayment Program for Research
Generally; 93.39, Academic Research
Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan
Repayment Program; 93.187, Undergraduate
Scholarship Program for Individuals from
Disadvantaged Backgrounds, National
Institutes of Health, HHS)
Dated: February 23, 2007.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–961 Filed 3–1–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Notice of Meeting: Secretary’s
Advisory Committee on Genetics,
Health, and Society
Pursuant to Public Law 92–463,
notice is hereby given of the twelfth
meeting of the Secretary’s Advisory
Committee on Genetics, Health, and
Society (SACGHS), U.S. Public Health
Service. The meeting will be held from
8 a.m. to approximately 5 p.m. on
Monday, March 26, 2007 and 8 a.m. to
approximately 5 p.m. on Tuesday,
March 27, 2007, at the Marriott Inn and
Conference Center, University of
Maryland—College Park, 3501
University Boulevard East, Adelphi, MD
20783. The meeting will be open to the
public with attendance limited to space
available. The meeting also will be Web
cast.
The agenda will focus on the
oversight of genetic testing, including
the role of the private sector in assuring
the quality and validity of genetic tests;
the impact of gene patents and licensing
practices on patient access to genetic
technologies, including a progress
report on the Committee’s study; and
the status of Federal genetic information
nondiscrimination legislation. The
Committee will be briefed on the
Secretary’s Personalized Health Care
Initiative and the work of the American
Health Information Community,
particularly its Personalized Health Care
Working Group. The Committee’s report
on the Policy Issues Associated with
Undertaking a New Large U.S.
Population Cohort Project on Genes,
Environment and Disease will be
E:\FR\FM\02MRN1.SGM
02MRN1
9542
Federal Register / Vol. 72, No. 41 / Friday, March 2, 2007 / Notices
released at the meeting. There also will
be updates on the Committee’s draft
report on pharmacogenomics and
several Federal initiatives and activities.
Time will be provided each day for
public comments. The Committee
would welcome hearing from anyone
wishing to provide public comments on
any issue related to genetics, health and
society. Individuals who would like to
provide public comment should notify
the SACGHS Executive Secretary, Ms.
Sarah Carr, by telephone at 301–496–
9838 or e-mail at sc112c@nih.gov. The
SACGHS office is located at 6705
Rockledge Drive, Suite 750, Bethesda,
MD 20892. Anyone planning to attend
the meeting, who is in need of special
assistance, such as sign language
interpretation or other reasonable
accommodations, is also asked to
contact the Executive Secretary.
Under authority of 42 U.S.C. 217a,
Section 222 of the Public Health Service
Act, as amended, the Department of
Health and Human Services established
SACGHS to serve as a public forum for
deliberations on the broad range of
human health and societal issues raised
by the development and use of genetic
and genomic technologies and, as
warranted, to provide advice on these
views. The draft meeting agenda and
other information about SACGHS,
including information about access to
the Web cast, will be available at the
following Web site: https://
www4.od.nih.gov/oba/sacghs.htm.
Dated: February 22, 2007.
Anna Snouffer,
Acting Director, NIH Office of Federal
Advisory Committee Policy.
[FR Doc. 07–965 Filed 3–1–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
new agent development contract
resources for the preclinical
development of drugs and biologics.
The outcome of the evaluation will be
a decision whether NCI should support
the request and make available contract
resources for support through the RAID
program to the research community and
NCI new agent development for the
preclinical development of drugs and
biologics. The research proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the
proposed research projects, the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Rapid
Access to Intervention Development.
Date: March 20–21, 2007.
Time: 1 p.m.–5 p.m.
Agenda: To evaluate the Rapid Access to
Intervention Development Portfolio.
Place: National Institutes of Health,
Executive Plaza North, Conference Room J,
6130 Executive Boulevard, Rockville, MD
20852.
Contact Person: Phyllis G. Bryant,
Executive Secretary, Program Analyst,
Developmental Therapeutics Program,
National Cancer Institute, NIH, 6130
Executive Boulevard, Rm. 8022, Bethesda,
MD 20892. (301) 496–8720.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: February 22, 2007
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–968 Filed 3–1–07; 8:45 am]
pwalker on PROD1PC71 with NOTICES
National Cancer Institute; Notice of
Closed Meeting
BILLING CODE 4140–01–M
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The purpose of this
meeting is to evaluate proposals for
support through the RAID program by
making available to the research
community, on a competitive basis, NCI
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
VerDate Aug<31>2005
18:44 Mar 01, 2007
Jkt 211001
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
Board of Scientific Counselors for Basic
Sciences National Cancer Institute. The
meeting will be closed to the public as
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
indicated below in accordance with the
provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
National Cancer Institute, including
consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Board of Scientific
Counselors for Basic Sciences National
Cancer Institute.
Date: March 4–5, 2007.
Time: March 4, 2007, 6 p.m. to 10:15 p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: Double Tree Hotel, 8120 Wisconsin
Avenue, Bethesda, MD 20814.
Time: March 5, 2007, 8 a.m. to 10 a.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health,
National Cancer Institute, 9000 Rockville
Pike, Building 31, Conference Room 6,
Bethesda, MD 20892.
Contact Person: Florence E. Farber, PhD,
Executive Secretary, Office of the Director,
National Cancer Institute, National Institutes
of Health, 6116 Executive Boulevard, Room
2115, Bethesda, MD 20892, 301–496–7628,
ff6p@nih.gov.
This notice is being published less than 15
days prior to meeting due to scheduling
conflicts.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: February 23, 2007.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–970 Filed 3–1–07; 8:45 am]
BILLING CODE 4140–01–M
E:\FR\FM\02MRN1.SGM
02MRN1
Agencies
[Federal Register Volume 72, Number 41 (Friday, March 2, 2007)]
[Notices]
[Pages 9541-9542]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-965]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Notice of Meeting: Secretary's Advisory Committee on Genetics,
Health, and Society
Pursuant to Public Law 92-463, notice is hereby given of the
twelfth meeting of the Secretary's Advisory Committee on Genetics,
Health, and Society (SACGHS), U.S. Public Health Service. The meeting
will be held from 8 a.m. to approximately 5 p.m. on Monday, March 26,
2007 and 8 a.m. to approximately 5 p.m. on Tuesday, March 27, 2007, at
the Marriott Inn and Conference Center, University of Maryland--College
Park, 3501 University Boulevard East, Adelphi, MD 20783. The meeting
will be open to the public with attendance limited to space available.
The meeting also will be Web cast.
The agenda will focus on the oversight of genetic testing,
including the role of the private sector in assuring the quality and
validity of genetic tests; the impact of gene patents and licensing
practices on patient access to genetic technologies, including a
progress report on the Committee's study; and the status of Federal
genetic information nondiscrimination legislation. The Committee will
be briefed on the Secretary's Personalized Health Care Initiative and
the work of the American Health Information Community, particularly its
Personalized Health Care Working Group. The Committee's report on the
Policy Issues Associated with Undertaking a New Large U.S. Population
Cohort Project on Genes, Environment and Disease will be
[[Page 9542]]
released at the meeting. There also will be updates on the Committee's
draft report on pharmacogenomics and several Federal initiatives and
activities.
Time will be provided each day for public comments. The Committee
would welcome hearing from anyone wishing to provide public comments on
any issue related to genetics, health and society. Individuals who
would like to provide public comment should notify the SACGHS Executive
Secretary, Ms. Sarah Carr, by telephone at 301-496-9838 or e-mail at
sc112c@nih.gov. The SACGHS office is located at 6705 Rockledge Drive,
Suite 750, Bethesda, MD 20892. Anyone planning to attend the meeting,
who is in need of special assistance, such as sign language
interpretation or other reasonable accommodations, is also asked to
contact the Executive Secretary.
Under authority of 42 U.S.C. 217a, Section 222 of the Public Health
Service Act, as amended, the Department of Health and Human Services
established SACGHS to serve as a public forum for deliberations on the
broad range of human health and societal issues raised by the
development and use of genetic and genomic technologies and, as
warranted, to provide advice on these views. The draft meeting agenda
and other information about SACGHS, including information about access
to the Web cast, will be available at the following Web site: https://
www4.od.nih.gov/oba/sacghs.htm.
Dated: February 22, 2007.
Anna Snouffer,
Acting Director, NIH Office of Federal Advisory Committee Policy.
[FR Doc. 07-965 Filed 3-1-07; 8:45 am]
BILLING CODE 4140-01-M